Cargando…
Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer
Non-small cell lung cancer is the predominant type of lung cancer, resulting in high mortality worldwide. Digoxin, a cardiac glycoside, has recently been suggested to be a novel chemotherapeutic agent. Src is an oncogene that plays an important role in cancer progression and is therefore a potential...
Autores principales: | Lin, Sheng-Yi, Chang, Hsiu-Hui, Lai, Yi-Hua, Lin, Ching-Hsiung, Chen, Min-Hsuan, Chang, Gee-Chen, Tsai, Meng-Feng, Chen, Jeremy J. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425490/ https://www.ncbi.nlm.nih.gov/pubmed/25955608 http://dx.doi.org/10.1371/journal.pone.0123305 |
Ejemplares similares
-
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
por: Lai, Yi-Hua, et al.
Publicado: (2015) -
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
por: Lai, Yi-Hua, et al.
Publicado: (2017) -
Detecting Digoxin Toxicity by Artificial Intelligence-Assisted Electrocardiography
por: Chang, Da-Wei, et al.
Publicado: (2021) -
Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth
por: Weng, Chia-Wei, et al.
Publicado: (2022) -
Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)